<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Preparative regimens for hematopoietic cell transplantation
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Preparative regimens for hematopoietic cell transplantation
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Preparative regimens for hematopoietic cell transplantation
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Robert S Negrin, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Nelson J Chao, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Alan G Rosmarin, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Sep 11, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         The preparative or conditioning regimen is a critical element in the hematopoietic cell transplantation (HCT) procedure. The purpose of the preparative regimen is twofold:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         To provide adequate immunosuppression to prevent rejection of the transplanted graft
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         To eradicate the disease for which the transplant is being performed
        </p>
        <p>
        </p>
        <p>
         This topic will discuss various myeloablative conditioning (MAC), nonmyeloablative (NMA), and reduced intensity conditioning (RIC) regimens.
        </p>
        <p>
         Selection of a preparative regimen for a specific disease is discussed in association with that disease.
        </p>
        <p>
         Choice of a graft source, graft-versus-host disease, and other toxicities and complications of HCT are discussed separately.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/3537.html" rel="external">
          "Hematopoietic cell transplantation (HCT): Sources of hematopoietic stem/progenitor cells"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/3549.html" rel="external">
          "Clinical manifestations, diagnosis, and grading of acute graft-versus-host disease"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/3543.html" rel="external">
          "Treatment of acute graft-versus-host disease"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/3550.html" rel="external">
          "Treatment of chronic graft-versus-host disease"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          DEFINITIONS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Preparative regimens for HCT have variable intensity, toxicity, and dependence upon a graft-versus-tumor effect (
         <a class="graphic graphic_figure graphicRef87814" href="/z/d/graphic/87814.html" rel="external">
          figure 1
         </a>
         ). Preparative regimens for HCT have been termed myeloablative, reduced intensity, and nonmyeloablative. While full agreement has not been achieved, generally accepted definitions of these three types of regimens are as follows [
         <a href="#rid1">
          1-4
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Myeloablative
         </strong>
         – A myeloablative conditioning (MAC) regimen consists of a single agent or combination of agents expected to destroy the hematopoietic cells in the bone marrow and results in profound pancytopenia within one to three weeks from the time of administration. The resulting pancytopenia is long-lasting and usually irreversible unless hematopoiesis is restored by infusion of hematopoietic stem cells. Examples include total body irradiation ≥5 Gy in a single dose or
         <a class="drug drug_general" data-topicid="9173" href="/z/d/drug information/9173.html" rel="external">
          busulfan
         </a>
         &gt;8 mg/kg. (See
         <a class="local">
          'Myeloablative regimens'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Nonmyeloablative
         </strong>
         – A nonmyeloablative (NMA) regimen is one that will cause minimal cytopenia (but significant lymphopenia) by itself and may not require stem cell support. Examples include
         <a class="drug drug_general" data-topicid="8452" href="/z/d/drug information/8452.html" rel="external">
          fludarabine
         </a>
         plus
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         with or without antithymocyte globulin or total body irradiation ≤2 Gy with or without a purine analog. However, the transplant, when given in this setting, usually becomes myeloablative because the engrafting donor T cells will eventually eliminate host hematopoietic cells, allowing the establishment of donor hematopoiesis. (See
         <a class="local">
          'NMA and RIC regimens'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Reduced intensity
         </strong>
         – Reduced intensity conditioning (RIC) regimens are an intermediate category of regimens that do not fit the definition of myeloablative or nonmyeloablative. Such regimens cause cytopenias, which may be prolonged and result in significant morbidity and mortality and require hematopoietic stem cell support. Regimens generally considered as reduced intensity include ≤8 mg/kg of
         <a class="drug drug_general" data-topicid="9173" href="/z/d/drug information/9173.html" rel="external">
          busulfan
         </a>
         , or ≤140 mg/m
         <sup>
          2
         </sup>
         of
         <a class="drug drug_general" data-topicid="9605" href="/z/d/drug information/9605.html" rel="external">
          melphalan
         </a>
         .
        </p>
        <p>
        </p>
        <p>
         Importantly, this nomenclature was designed to reflect the acute regimen related toxicity rather than the overall efficacy of the transplant on the underlying disease state. In addition, these definitions serve only as guidelines, and it is often difficult in practice to know what impact a regimen will have in the absence of transplantation. Multicenter randomized trials are necessary to better compare the efficacy and toxicity of these regimens in particular disease states.
        </p>
        <p class="headingAnchor" id="H89394187">
         <span class="h1">
          CHOICE OF REGIMEN
         </span>
         <span class="headingEndMark">
          —
         </span>
         There is no optimal preparative regimen for all patients who undergo HCT, and clinical practice varies among institutions. The choice of a preparative regimen should take into account the recipient's comorbidities, underlying condition, disease status, donor, and graft source. Comparisons of preparative regimens are discussed below. (See
         <a class="local">
          'MAC versus RIC regimens'
         </a>
         below.)
        </p>
        <p>
         The following principles should be considered in choosing a preparative regimen:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Recipient comorbidities
         </strong>
         – A patient's underlying comorbidities often dictate the type of conditioning regimen that may be offered. Patients with substantial comorbidities and older patients are not candidates for myeloablative conditioning regimens but may be candidates for a reduced intensity conditioning (RIC) regimen or a nonmyeloablative (NMA) regimen. (See
         <a class="medical medical_review" href="/z/d/html/16870.html" rel="external">
          "Determining eligibility for allogeneic hematopoietic cell transplantation"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Underlying condition
         </strong>
         – The underlying condition may influence the choice of preparative regimen. For a patient with hematologic malignancy or proliferative condition (eg, thalassemia), eradication of the host's hematopoietic stem cells is an important goal and a myeloablative regimen would be preferred. In contrast, for patients with aplastic anemia or certain immunodeficiency states, eradication is not required, and the preparative regimen is primarily focused on immunosuppression to allow for engraftment and a less intensive regimen may be appropriate.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Certain inherited bone marrow failure conditions (eg, Fanconi anemia) are particularly susceptible to the toxicities of chemotherapy and radiation and should receive a lower intensity preparative regimen. (See
         <a class="medical medical_review" href="/z/d/html/132753.html" rel="external">
          "Hematopoietic cell transplantation (HCT) for inherited bone marrow failure syndromes (IBMFS)", section on 'Conditioning regimen'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Disease status
         </strong>
         – Myeloablative conditioning (MAC) regimens are preferred for patients with hematologic malignancies that are not in complete remission at the time of transplantation. Total body irradiation may be preferred in some settings due to its potential eradication of tumor cells in sanctuary sites (eg, central nervous system, gonads) that are not sufficiently penetrated by many chemotherapy agents.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Risk of rejection
         </strong>
         – Graft rejection is more likely when there is increasing human leukocyte antigen (HLA) disparity in major histocompatibility antigens (eg, HLA-mismatch), in recipients who have been exposed to minor histocompatability antigens (eg, multiple prior blood transfusions), following the infusion of grafts with a low stem cell dose, and with T cell depleted grafts. Graft rejection is less likely with increased stem cell dose, use of peripheral blood progenitor cells rather than bone marrow cells, high T cell dose in the graft, and the use of ATG in the preparative regimen. Graft rejection is not generally considered a risk in autologous HCT. (See
         <a class="medical medical_review" href="/z/d/html/16563.html" rel="external">
          "Selection of an umbilical cord blood graft for hematopoietic cell transplantation", section on 'Cell dose'
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         Often, MAC regimens are preferred for young patients with a good performance status undergoing allogeneic HCT given the larger experience with these regimens. MAC regimens are also the cornerstone of autologous HCT. RIC or nonmyeloablative regimens may be considered for patients who are not candidates for MAC regimens in whom the underlying disease has been well controlled. A choice between MAC, RIC, and NMA regimens is largely based on institutional preferences, center experience, resources available, and the principles described above.
        </p>
        <p>
         Prospective randomized trials will be required to compare MAC with NMA regimens for the treatment of a particular disease. In general, MAC regimens are used for autologous HCT and in the allogeneic setting for the treatment of patients not in remission.
        </p>
        <p class="headingAnchor" id="H5">
         <span class="h1">
          MYELOABLATIVE REGIMENS
         </span>
        </p>
        <p class="headingAnchor" id="H89396143">
         <span class="h2">
          Examples of MAC regimens
         </span>
         <span class="headingEndMark">
          —
         </span>
         As described above, a myeloablative conditioning (MAC) regimen consists of a single agent or combination of agents expected to destroy the hematopoietic cells in the bone marrow and results in profound pancytopenia within one to three weeks from the time of administration [
         <a href="#rid4">
          4
         </a>
         ]. The resulting pancytopenia is long-lasting, usually irreversible unless hematopoiesis is restored by infusion of hematopoietic stem cells. Commonly employed myeloablative regimens include (
         <a class="graphic graphic_table graphicRef90901" href="/z/d/graphic/90901.html" rel="external">
          table 1
         </a>
         ) [
         <a href="#rid5">
          5
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Cy/TBI
         </strong>
         – The Cy/TBI regimen combines
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         120 mg/kg total dose administered over two days with total body irradiation (TBI; 12 to 14 Gy) administered over four days.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Bu4/Cy
         </strong>
         – The Bu4/Cy regimen combines intravenous
         <a class="drug drug_general" data-topicid="9173" href="/z/d/drug information/9173.html" rel="external">
          busulfan
         </a>
         10 to 12 mg/kg total dose administered over four days with
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         120 mg/kg administered over two days.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Flu/Bu4
         </strong>
         – The Flu/Bu4 regimen combines
         <a class="drug drug_general" data-topicid="9173" href="/z/d/drug information/9173.html" rel="external">
          busulfan
         </a>
         16 mg/kg orally or 12.8 mg/kg by vein with
         <a class="drug drug_general" data-topicid="8452" href="/z/d/drug information/8452.html" rel="external">
          fludarabine
         </a>
         120 to 180 mg/m
         <sup>
          2
         </sup>
         administered over four days.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          BEAM
         </strong>
         – The BEAM regimen combines BCNU 300 mg/m
         <sup>
          2
         </sup>
         over one day,
         <a class="drug drug_general" data-topicid="8430" href="/z/d/drug information/8430.html" rel="external">
          etoposide
         </a>
         400 to 800 mg/m
         <sup>
          2
         </sup>
         over four days, cytosine arabinoside 800 to 1600 mg/m
         <sup>
          2
         </sup>
         over four days, and
         <a class="drug drug_general" data-topicid="9605" href="/z/d/drug information/9605.html" rel="external">
          melphalan
         </a>
         140 mg/m
         <sup>
          2
         </sup>
         over one day. BEAM is the most commonly employed myeloablative preparative regimen for patients with non-Hodgkin or Hodgkin lymphoma.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Melphalan
         </strong>
         –
         <a class="drug drug_general" data-topicid="9605" href="/z/d/drug information/9605.html" rel="external">
          Melphalan
         </a>
         200 mg/m
         <sup>
          2
         </sup>
         is commonly employed as the preparative regimen prior to autologous HCT for multiple myeloma. A lower dose 140 mg/m
         <sup>
          2
         </sup>
         is used in older patients (ie, &gt;70 years), those with renal dysfunction, or patients with multiple comorbidities. (See
         <a class="medical medical_review" href="/z/d/html/6656.html" rel="external">
          "Multiple myeloma: Use of hematopoietic cell transplantation", section on 'Preparative chemotherapy'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          CBV
         </strong>
         – The CBV regimen combines a single dose of
         <a class="drug drug_general" data-topicid="9206" href="/z/d/drug information/9206.html" rel="external">
          carmustine
         </a>
         300 to 500 mg/m
         <sup>
          2
         </sup>
         followed by
         <a class="drug drug_general" data-topicid="8430" href="/z/d/drug information/8430.html" rel="external">
          etoposide
         </a>
         600 to 2400 mg/m
         <sup>
          2
         </sup>
         plus
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         4.8 g/m
         <sup>
          2
         </sup>
         to 7.2 g/m
         <sup>
          2
         </sup>
         over a four-day period. This regimen is commonly used for the treatment of patients with lymphomas.
        </p>
        <p>
        </p>
        <p>
         A number of variations on these myeloablative regimens have been employed at centers throughout the world. They were developed by escalating the dose of either radiation or a particular drug to the maximally tolerated dose. Drugs with non-overlapping toxicities were employed in an effort to avoid synergistic injury to a particular organ (
         <a class="graphic graphic_table graphicRef54359" href="/z/d/graphic/54359.html" rel="external">
          table 2
         </a>
         ). (See
         <a class="local">
          'Definitions'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H89396547">
         <span class="h2">
          MAC toxicity
         </span>
         <span class="headingEndMark">
          —
         </span>
         All MAC regimens have side effects that can be life-threatening. In addition to myelotoxicity, common toxicities include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Mucositis (see
         <a class="medical medical_review" href="/z/d/html/15803.html" rel="external">
          "Early complications of hematopoietic cell transplantation", section on 'Oral mucositis'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1152.html" rel="external">
          "Oral toxicity associated with systemic anticancer therapy"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Nausea and vomiting (see
         <a class="medical medical_review" href="/z/d/html/1151.html" rel="external">
          "Prevention of chemotherapy-induced nausea and vomiting in adults"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Alopecia (see
         <a class="medical medical_review" href="/z/d/html/1156.html" rel="external">
          "Alopecia related to systemic cancer therapy"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Diarrhea (see
         <a class="medical medical_review" href="/z/d/html/2824.html" rel="external">
          "Chemotherapy-associated diarrhea, constipation and intestinal perforation: pathogenesis, risk factors, and clinical presentation"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Rash
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Peripheral neuropathies (see
         <a class="medical medical_review" href="/z/d/html/2836.html" rel="external">
          "Overview of neurologic complications of conventional non-platinum cancer chemotherapy"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2826.html" rel="external">
          "Overview of neurologic complications of platinum-based chemotherapy"
         </a>
         )
        </p>
        <p>
        </p>
        <p>
         Infertility, which can be devastating to young patients, is almost universal when using myeloablative regimens. This can be addressed with sperm cryopreservation for male patients, assuming they have adequate sperm number and function. Embryo or oocyte cryopreservation in female patients can also be attempted, with generally less success. (See
         <a class="medical medical_review" href="/z/d/html/7440.html" rel="external">
          "Fertility and reproductive hormone preservation: Overview of care prior to gonadotoxic therapy or surgery"
         </a>
         .)
        </p>
        <p>
         Pulmonary and hepatic toxicity are also relatively common. As an example,
         <a class="drug drug_general" data-topicid="9173" href="/z/d/drug information/9173.html" rel="external">
          busulfan
         </a>
         , which is a component of many preparative regimens, can produce both interstitial lung disease and hepatic sinusoidal obstructive syndrome [
         <a href="#rid6">
          6,7
         </a>
         ]. As a result, it is imperative that patients be screened for comorbidities prior to initiating the preparative regimen to avoid unnecessary risk. Monitoring of busulfan pharmacokinetics, a common practice, can also reduce the risk of these complications. (See
         <a class="medical medical_review" href="/z/d/html/4348.html" rel="external">
          "Busulfan-induced pulmonary injury"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/16870.html" rel="external">
          "Determining eligibility for allogeneic hematopoietic cell transplantation"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/129806.html" rel="external">
          "Hepatic sinusoidal obstruction syndrome (veno-occlusive disease) in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H6">
         <span class="h2">
          Radiation-containing regimens
         </span>
         <span class="headingEndMark">
          —
         </span>
         Total body irradiation (TBI) has been the mainstay of preparative regimens since the inception of HCT, based upon early studies in the dog and other animal models. Initial preparative regimens included TBI administered as a single dose using opposing Cobalt-60 sources [
         <a href="#rid8">
          8
         </a>
         ]. At present, TBI-based regimens typically fractionate the radiation and administer the total dose over several days, typically four, which helps decrease toxicity and increase tolerability (
         <a class="graphic graphic_table graphicRef90901" href="/z/d/graphic/90901.html" rel="external">
          table 1
         </a>
         ) [
         <a href="#rid9">
          9
         </a>
         ]. Partial lung shielding is included in an effort to reduce the potential for irreversible lung injury.
        </p>
        <p>
         The maximally tolerated dose of TBI is approximately 15 Gy. Higher doses produce excessive nonhematologic toxicity, primarily to the lungs, but also to other organs including the heart. Two randomized trials evaluated the efficacy of different doses of TBI (12 and 16 Gy) plus
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         , prior to allogeneic HCT in patients with acute myeloid leukemia in first remission and chronic myeloid leukemia in the chronic phase [
         <a href="#rid10">
          10,11
         </a>
         ]. Decreased relapse rates were observed with the higher TBI dose (eg, 12 versus 35 percent at three years in patients with acute myeloid leukemia), but overall survival was similar due primarily to increased transplant-related mortality at the higher doses (eg, 32 versus 12 percent at three years) [
         <a href="#rid10">
          10
         </a>
         ]. This observation has provided one of the major rationales for developing radiolabeled monoclonal antibodies as part of the preparative regimen. (See
         <a class="local">
          'Radiolabeled Mabs'
         </a>
         below.)
        </p>
        <p>
         In the initial regimens, TBI was combined with
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         (Cy) and this Cy/TBI combination is still widely used. In Cy/TBI, cyclophosphamide is usually given at a dose of 60 mg/kg of adjusted ideal body weight on each of two successive days [
         <a href="#rid12">
          12-14
         </a>
         ]. Attempts at further intensification, either by increasing the TBI dose or adding other agents have been unsuccessful at improving overall survival largely due to an increase in non-relapse mortality. TBI has also been combined with other chemotherapy agents. As examples:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="8430" href="/z/d/drug information/8430.html" rel="external">
          Etoposide
         </a>
         (VP16) has been given with fractionated TBI at a maximally tolerated dose of 60 mg/kg [
         <a href="#rid15">
          15
         </a>
         ], with excellent results having been obtained in large numbers of patients [
         <a href="#rid16">
          16,17
         </a>
         ]. In addition, VP 16 has been combined with
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         and TBI (TBI/CY/VP16) in both the autologous and allogeneic setting, in an attempt to reduce relapse rates in patients with high risk or advanced stage hematologic malignancies [
         <a href="#rid18">
          18-20
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         High dose
         <a class="drug drug_general" data-topicid="9314" href="/z/d/drug information/9314.html" rel="external">
          cytarabine
         </a>
         (cytosine arabinoside, usually at a dose of 3 g every 12 hours for six days) also has been given with TBI, with and without
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         , in patients with acute leukemia [
         <a href="#rid21">
          21,22
         </a>
         ]. The rationale for this approach is to reduce the likelihood of relapse via the antileukemic activity of cytarabine. However, the possible superiority of using cytarabine rather than cyclophosphamide remains unproven [
         <a href="#rid23">
          23
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         Fractionated TBI has been relatively difficult to standardize in multi-institutional trials, due to differences in dose rates, shielding, and center-specific techniques. Dose rates differ by machine and lower total doses must be given when using machines with a high dose rate in order to limit toxicity. Fractionation reduces the incidence and severity of acute and late complications. Lower total doses may decrease toxicity but increase the risk of graft failure and disease recurrence. In contrast, higher doses decrease graft rejection and disease relapse but increase treatment-related morbidity and mortality.
        </p>
        <p>
         The major limitations of fractionated TBI include mucositis, lung toxicity, infertility, and the relatively sophisticated instrumentation required to effectively administer this treatment. However, keratinocyte growth factor (
         <a class="drug drug_general" data-topicid="10161" href="/z/d/drug information/10161.html" rel="external">
          palifermin
         </a>
         ) has been successful in reducing the risk of mucositis following radiation-containing regimens. (See
         <a class="medical medical_review" href="/z/d/html/15803.html" rel="external">
          "Early complications of hematopoietic cell transplantation", section on 'Oral mucositis'
         </a>
         .)
        </p>
        <p>
         Long-term complications following TBI used as part of a HCT preparative regimen are common. In one study of 186 adults surviving at least one year following TBI and HCT, who were followed for a median time of four years (range one to 11 years), the most commonly seen complications included [
         <a href="#rid24">
          24
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Asymptomatic alterations in pulmonary function – 19 percent [
         <a href="#rid25">
          25
         </a>
         ]
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Cataracts – 15 percent; surgery was necessary in 57 percent
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Sicca syndrome – 13 percent
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hypothyroidism – 6.5 percent; one-half required medical treatment
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Thyroiditis – 3 percent
        </p>
        <p>
        </p>
        <p>
         Many centers are transitioning away from the use of radiation-based regimens in preference for chemotherapy-based regimens.
        </p>
        <p class="headingAnchor" id="H7">
         <span class="h2">
          Chemotherapy without RT
         </span>
         <span class="headingEndMark">
          —
         </span>
         A number of regimens have been developed in which TBI is replaced with additional chemotherapeutic agents [
         <a href="#rid26">
          26
         </a>
         ]. These approaches were primarily developed for autologous transplantation but have also been used widely in the allogeneic setting. The primary advantage of regimens that lack TBI is reduced toxicity. In addition, the cost is lower, the regimen is easier to administer and schedule, and radiation can still be given to sites of disease following the transplant [
         <a href="#rid27">
          27
         </a>
         ].
        </p>
        <p>
         Drug combinations have been selected based upon the biologic activity of the particular drug, the ability to escalate the dose of the drug, and non-overlapping toxicities when delivering the drugs at maximally tolerated dosages. The most widely used non-radiation-containing regimen is the combination of
         <a class="drug drug_general" data-topicid="9173" href="/z/d/drug information/9173.html" rel="external">
          busulfan
         </a>
         and
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         (Bu/Cy) [
         <a href="#rid6">
          6,28-34
         </a>
         ]. BCNU (
         <a class="drug drug_general" data-topicid="9206" href="/z/d/drug information/9206.html" rel="external">
          carmustine
         </a>
         ),
         <a class="drug drug_general" data-topicid="8430" href="/z/d/drug information/8430.html" rel="external">
          etoposide
         </a>
         , cytosine arabinoside and
         <a class="drug drug_general" data-topicid="9605" href="/z/d/drug information/9605.html" rel="external">
          melphalan
         </a>
         (BEAM) or BCNU, etoposide and cyclophosphamide are widely used preparative regimens for patients with non-Hodgkin or Hodgkin lymphoma [
         <a href="#rid35">
          35
         </a>
         ]. High dose melphalan is commonly employed as a myeloablative preparative regimen prior to autologous HCT for multiple myeloma. Different doses and schedules of these drugs have been employed at various transplant centers, making it difficult to compare results with this regimen from one study to the next [
         <a href="#rid11">
          11,36-40
         </a>
         ]. (See
         <a class="local">
          'Examples of MAC regimens'
         </a>
         above.)
        </p>
        <p>
         Initial Bu/Cy regimens used high dose oral
         <a class="drug drug_general" data-topicid="9173" href="/z/d/drug information/9173.html" rel="external">
          busulfan
         </a>
         , which had to be administered prior to emetogenic agents, had variable pharmacokinetics, and was associated with high rates of hepatic sinusoidal obstructive syndrome and seizures [
         <a href="#rid41">
          41
         </a>
         ]. Modern Bu/Cy regimens use an intravenous formulation of busulfan, which has less pharmacokinetic variability and is associated with fewer toxicities (less emetogenic, less liver toxicity) [
         <a href="#rid42">
          42
         </a>
         ]. The administration of adjusted dose IV busulfan, where the dose of busulfan is adjusted based upon pharmacologic evaluation, with
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         has resulted in excellent outcomes with improved tolerability [
         <a href="#rid43">
          43
         </a>
         ]. Prophylactic anticonvulsant therapy should be initiated prior to the administration of busulfan.
        </p>
        <p>
         A significant problem with
         <a class="drug drug_general" data-topicid="9206" href="/z/d/drug information/9206.html" rel="external">
          carmustine
         </a>
         (BCNU)-containing regimens has been the relatively high incidence of pulmonary toxicity, particularly in patients who have received prior radiotherapy to the chest [
         <a href="#rid44">
          44,45
         </a>
         ]. This condition typically responds to corticosteroids (approximate
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         dose 1 mg/kg) especially in early disease. An approach to minimizing lung toxicity is the combination of
         <a class="drug drug_general" data-topicid="9173" href="/z/d/drug information/9173.html" rel="external">
          busulfan
         </a>
         ,
         <a class="drug drug_general" data-topicid="9605" href="/z/d/drug information/9605.html" rel="external">
          melphalan
         </a>
         , and
         <a class="drug drug_general" data-topicid="9992" href="/z/d/drug information/9992.html" rel="external">
          thiotepa
         </a>
         , followed by autologous peripheral blood progenitor cells in patients with aggressive or relapsed lymphoma [
         <a href="#rid46">
          46
         </a>
         ]. Among the 40 patients treated with this regimen, interstitial pneumonitis developed in only one patient who had received prior lung radiotherapy. (See
         <a class="medical medical_review" href="/z/d/html/4354.html" rel="external">
          "Nitrosourea-induced pulmonary injury"
         </a>
         .)
        </p>
        <p>
         The preferred preparative regimen may also vary with the nature of the underlying disease. Among patients with aplastic anemia, for example, it is desirable to increase the degree of immunosuppression (to prevent rejection of the graft) while avoiding excessive myelotoxicity. This has been successfully achieved with the combination of
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         and antithymocyte globulin [
         <a href="#rid47">
          47
         </a>
         ]. (See
         <a class="local">
          'Choice of regimen'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/7089.html" rel="external">
          "Hematopoietic cell transplantation for aplastic anemia in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H8">
         <span class="h2">
          Comparison of RT with chemotherapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         It is difficult to compare the relative efficacy of the large number of different myeloablative preparative regimens that have been developed, since there are few direct comparisons in randomized clinical trials. In addition, it is likely that patient selection has a large impact on the results obtained, making it difficult to assess the impact of any given preparative regimen from the large number of phase II trials reported in the literature. An instructive example was reported in a retrospective cohort study which compared a radiation-containing preparative regimen (TBI/
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         /
         <a class="drug drug_general" data-topicid="8430" href="/z/d/drug information/8430.html" rel="external">
          etoposide
         </a>
         ) with a chemotherapy-only regimen (BEAM) in patients with non-Hodgkin lymphoma undergoing autologous peripheral blood stem cell transplantation [
         <a href="#rid48">
          48
         </a>
         ]. The TBI-containing regimen resulted in relapse-free and overall survivals similar to that after BEAM. Further analysis indicated that transplantation before the year 2000, rather than the conditioning regimen, was a more important predictive factor for long-term outcome.
        </p>
        <p>
         Despite these difficulties, a number of retrospective and randomized trials, including one meta-analysis, have compared Bu/Cy with Cy/TBI [
         <a href="#rid6">
          6,29,49,50
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The International Bone Marrow Transplant Registry retrospectively compared outcomes following allogeneic HCT in 381 human leukocyte antigen (HLA)-matched sibling transplants receiving Bu/Cy with 200 transplants using Cy/TBI for acute myeloid leukemia in first remission [
         <a href="#rid50">
          50
         </a>
         ]. The incidence of hepatic sinusoidal obstructive syndrome (SOS, previously called hepatic veno-occlusive disease [VOD]), was higher with Bu/Cy than with Cy/TBI (13 versus 6 percent) and the relapse risk was higher with Bu/Cy (relative risk 1.7, 95% CI 1.05-2.81). Nevertheless, there were no differences in treatment-related mortality, risk for acute or chronic graft-versus-host disease, leukemia-free survival, or overall survival between the two treatments.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A meta-analysis of five prospective randomized studies comparing Bu/Cy with Cy/TBI came to similar conclusions [
         <a href="#rid49">
          49
         </a>
         ], with an increased risk of hepatic SOS in the Bu/Cy group (odds ratio 2.5, 95% CI 1.2-5.2) but no significant differences in acute or chronic GVHD, interstitial pneumonitis, disease-free survival, or overall survival.
        </p>
        <p>
        </p>
        <p>
         These studies did not include dose adjustment of
         <a class="drug drug_general" data-topicid="9173" href="/z/d/drug information/9173.html" rel="external">
          busulfan
         </a>
         based on pharmacokinetics, which may have an impact on regimen-related complications, such as hepatic SOS. Given these results, many groups have utilized Bu/Cy preparation for patients with myeloid diseases rather than TBI-based regimens. (See
         <a class="medical medical_review" href="/z/d/html/129806.html" rel="external">
          "Hepatic sinusoidal obstruction syndrome (veno-occlusive disease) in adults", section on 'Modifiable risk factors'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H89394696">
         <span class="h1">
          NMA AND RIC REGIMENS
         </span>
        </p>
        <p class="headingAnchor" id="H89394738">
         <span class="h2">
          General principles
         </span>
         <span class="headingEndMark">
          —
         </span>
         Among patients with leukemia treated with allogeneic HCT, an important contributing factor is a graft-versus-tumor (GVT) effect mediated by donor immunocompetent cells [
         <a href="#rid51">
          51
         </a>
         ]. The importance of GVT is illustrated by the different outcomes with grafts from identical twin and nonidentical donors. Patients who have an identical twin donor do not develop either graft-versus-host disease (GVHD) or GVT and are therefore at higher risk of relapse of the underlying malignant disease than similar patients transplanted with human leukocyte antigen (HLA)-matched but nonidentical sibling donors (who develop both GVHD and GVT). (See
         <a class="medical medical_review" href="/z/d/html/3546.html" rel="external">
          "Biology of the graft-versus-tumor effect following hematopoietic cell transplantation"
         </a>
         .)
        </p>
        <p>
         The GVT effect requires the engraftment of donor type immunocompetent cells, which does not necessarily require a high dose myeloablative preparative regimen. As a result, the possibility of achieving donor-specific engraftment using nonmyeloablative (NMA) or reduced intensity conditioning (RIC) regimens has been extensively explored [
         <a href="#rid2">
          2,52-56
         </a>
         ]. This approach, which relies more on donor cellular immune effects and less on the cytotoxic effects of the preparative regimen to control the underlying disease [
         <a href="#rid51">
          51,57-59
         </a>
         ], permits transplantation in older, as well as high-risk, heavily pretreated patients of any age, with an attendant decrease in regimen-related toxicity and treatment-related mortality [
         <a href="#rid60">
          60-68
         </a>
         ]. (See
         <a class="local">
          'Definitions'
         </a>
         above.)
        </p>
        <p>
         In many instances, cancer cells cannot be eradicated entirely by high dose chemotherapy alone (eg, multiple myeloma), or patients with these disorders are too ill because of age and/or co-morbidities to tolerate myeloablative chemotherapy followed by transplantation [
         <a href="#rid61">
          61,69,70
         </a>
         ]. Many of the observed long-term tumor responses have been brought about by immunologic antitumor effects (ie, the GVT effect) generated by the allograft (eg, donor lymphocyte infusion in CML relapsing after allogeneic HCT) [
         <a href="#rid51">
          51,71
         </a>
         ].
        </p>
        <p>
         Importantly, not all diseases are equally susceptible to GVT effects. Follicular lymphoma, chronic lymphocytic leukemia, mantle cell lymphoma, and chronic myeloid leukemia appear particularly responsive, whereas acute lymphoblastic leukemia and Hodgkin lymphoma are relatively resistant. The biological explanation for these observations remains elusive. As an example, in one analysis of 834 patients who had undergone allogeneic HCT, the overall relapse rate per patient year was 0.36. Patients with chronic lymphocytic leukemia, multiple myeloma in remission, low grade or mantle cell lymphoma, and high grade non-Hodgkin lymphoma had the lowest rates (0 to 0.24), whereas those with advanced myeloid and lymphoid malignancies had rates of more than 0.52 [
         <a href="#rid72">
          72
         </a>
         ].
        </p>
        <p>
         Additional studies need to determine the relative role of this transplant approach, including such variables as the age and overall comorbidity status of the recipient, presence or absence of complete or partial remission at the time of HCT and clinical aggressiveness of the underlying disorder, the degree of HLA matching of the donor, and the agents and doses used in the reduced intensity conditioning regimens and GVHD prophylaxis [
         <a href="#rid72">
          72-77
         </a>
         ]. However, these approaches have been tolerated reasonably well even in older patients who have significant medical comorbidities, allowing for many more patients to be treated with transplantation. This is important because many of the diseases for which allogeneic HCT has been successful typically occur in patients in their fifth to seventh decades of life.
        </p>
        <p class="headingAnchor" id="H9953070">
         <span class="h2">
          Examples of NMA/RIC regimens
         </span>
         <span class="headingEndMark">
          —
         </span>
         Specifics regarding the definitions of RIC and NMA preparative regimens are the subject of ongoing debate (
         <a class="graphic graphic_table graphicRef90901" href="/z/d/graphic/90901.html" rel="external">
          table 1
         </a>
         ). In general, RIC regimens have toxicity profiles that are significantly lower than myeloablative conditioning (MAC) regimens and higher than NMA regimens.
        </p>
        <p>
         Commonly employed NMA regimens include [
         <a href="#rid5">
          5
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Flu/TBI
         </strong>
         – The Flu/TBI regimen combines
         <a class="drug drug_general" data-topicid="8452" href="/z/d/drug information/8452.html" rel="external">
          fludarabine
         </a>
         90 mg/m
         <sup>
          2
         </sup>
         total dose administered over three days with low dose total body irradiation (TBI, 2 Gy) administered on the day of graft infusion.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          TLI/ATG
         </strong>
         – The TLI/ATG regimen combines total lymphoid irradiation (TLI, 8 to 12 cGy) administered over 11 days with anti-thymocyte globulin (ATG; 1.25 mg/kg) administered over five days. In this approach, TLI and ATG appear to alter the host immune profile to favor regulatory natural killer T cells that suppress GVHD but retain graft antitumor activity [
         <a href="#rid78">
          78
         </a>
         ]. Initial studies of this approach appeared promising, with an apparent reduction in acute GVHD risk with retention of GVT effects and very low transplant related mortality [
         <a href="#rid79">
          79,80
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         In one of the few randomized studies, compared with Flu/TBI, TLI/ATG resulted in a lower risk of non-relapse mortality and a higher risk of relapse with similar rates of overall survival (OS) and event-free survival (EFS) [
         <a href="#rid81">
          81
         </a>
         ].
        </p>
        <p>
         Commonly employed RIC regimens include [
         <a href="#rid5">
          5
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Flu/Mel
         </strong>
         – The Flu/Mel regimen combines
         <a class="drug drug_general" data-topicid="8452" href="/z/d/drug information/8452.html" rel="external">
          fludarabine
         </a>
         (125 to 150 mg/m
         <sup>
          2
         </sup>
         total dose) administered over five days with
         <a class="drug drug_general" data-topicid="9605" href="/z/d/drug information/9605.html" rel="external">
          melphalan
         </a>
         (140 mg/m
         <sup>
          2
         </sup>
         ) administered over two days.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Flu/Bu2
         </strong>
         – The Flu/Bu2 regimen combines
         <a class="drug drug_general" data-topicid="8452" href="/z/d/drug information/8452.html" rel="external">
          fludarabine
         </a>
         (150 to 160 mg/m
         <sup>
          2
         </sup>
         ) total dose administered over four to five days with oral
         <a class="drug drug_general" data-topicid="9173" href="/z/d/drug information/9173.html" rel="external">
          busulfan
         </a>
         (8 to 10 mg/kg) administered over two to three days.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Flu/Cy
         </strong>
         – The Flu/Cy regimen combines
         <a class="drug drug_general" data-topicid="8452" href="/z/d/drug information/8452.html" rel="external">
          fludarabine
         </a>
         (150 to 180 mg/m
         <sup>
          2
         </sup>
         ) total dose administered over five to six days with
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         (120 to 140 mg/kg) administered over two days.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Flu/Bu/TT
         </strong>
         – This regimen combines
         <a class="drug drug_general" data-topicid="8452" href="/z/d/drug information/8452.html" rel="external">
          fludarabine
         </a>
         150 mg/m
         <sup>
          2
         </sup>
         total dose administered over three days with
         <a class="drug drug_general" data-topicid="9173" href="/z/d/drug information/9173.html" rel="external">
          busulfan
         </a>
         (8 mg/kg) administered over three days and
         <a class="drug drug_general" data-topicid="9992" href="/z/d/drug information/9992.html" rel="external">
          thiotepa
         </a>
         (5 to 10 mg/m
         <sup>
          2
         </sup>
         ) over one or two days, respectively.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Flu/Treo
         </strong>
         – This regimen combines
         <a class="drug drug_general" data-topicid="8452" href="/z/d/drug information/8452.html" rel="external">
          fludarabine
         </a>
         (150 mg/m
         <sup>
          2
         </sup>
         ) total dose over five days with
         <a class="drug drug_general" data-topicid="134625" href="/z/d/drug information/134625.html" rel="external">
          treosulfan
         </a>
         (10 g/m
         <sup>
          2
         </sup>
         daily two-hour infusion for three days) [
         <a href="#rid82">
          82
         </a>
         ]. Treosulfan is approved for use in Canada and Europe, but not in the United States.
        </p>
        <p>
        </p>
        <p>
         All of these regimens have shown promise and are being used by different centers. All have merit and appear to be reasonably well tolerated in older individuals and in patients with significant co-morbid medical conditions, including patients who have undergone prior autologous transplantation.
        </p>
        <p class="headingAnchor" id="H3000363872">
         <span class="h2">
          MAC versus RIC regimens
         </span>
         <span class="headingEndMark">
          —
         </span>
         It is difficult to directly compare efficacy and toxicity of MAC versus NMA/RIC or between various preparative regimens since there are few randomized clinical trials or other well-controlled studies. Patient selection has an important impact on outcomes and studies vary with regard to patient populations, underlying disease, remission status, and graft source. In general, compared with NMA/RIC regimens, MAC is associated with superior relapse-free survival (RFS), but increased treatment-related mortality (TRM); the effects offset one another, so overall survival (OS) is comparable with the two approaches.
        </p>
        <p>
         Examples of informative studies include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A multicenter phase 3 trial that included 272 patients with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) reported fewer relapses after MAC than after RIC, but there was no difference in survival [
         <a href="#rid83">
          83
         </a>
         ]. Compared with RIC, MAC was associated with superior RFS (68 versus 47 percent, respectively), but a higher rate of TRM (16 versus 4 percent); as a result, there was no difference in OS at 18 months. A subsequent analysis of this trial reported that the benefits of MAC were related to improved outcomes among patients who had measurable residual disease (MRD) prior to transplantation [
         <a href="#rid84">
          84
         </a>
         ]. Further details of this trial are presented separately. (See
         <a class="medical medical_review" href="/z/d/html/4533.html" rel="external">
          "Acute myeloid leukemia in younger adults: Post-remission therapy", section on 'NMA/RIC versus MAC regimens'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A prospective age-adapted strategy for adults with AML showed no difference in OS between MAC and RIC [
         <a href="#rid85">
          85
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Retrospective studies with AML or MDS suggested that RIC is associated with increased rates of relapse and less TRM [
         <a href="#rid86">
          86-94
         </a>
         ]. As a result, both approaches achieved similar OS, even though patients who received RIC were generally older and less fit.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H5644221">
         <span class="h2">
          Comparison of different RIC regimens
         </span>
         <span class="headingEndMark">
          —
         </span>
         Comparisons of different reduced intensity regimens are based on uncontrolled retrospective studies, as there are no randomized or well-controlled prospective trials [
         <a href="#rid95">
          95
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H89394744">
         <span class="h2">
          Minimal intensity (antibody) conditioning
         </span>
         <span class="headingEndMark">
          —
         </span>
         Some patients, such as those with severe organ toxicity and/or DNA/telomere repair defects, may be unable to tolerate MAC or even NMA regimens and may be candidates for minimal intensity conditioning. (See
         <a class="medical medical_review" href="/z/d/html/115988.html" rel="external">
          "Hematopoietic cell transplantation for severe combined immunodeficiencies"
         </a>
         .)
        </p>
        <p>
         This concept was tested in a phase I/II study of 16 high-risk patients who underwent allogeneic HCT for primary combined immunodeficiency. The conditioning regimen included the use of two rat anti-CD45 antibodies, an anti-CD52 antibody (
         <a class="drug drug_general" data-topicid="8725" href="/z/d/drug information/8725.html" rel="external">
          alemtuzumab
         </a>
         ),
         <a class="drug drug_general" data-topicid="8452" href="/z/d/drug information/8452.html" rel="external">
          fludarabine
         </a>
         , and low-dose
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         . Results included [
         <a href="#rid96">
          96
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Rates of clinically significant acute and chronic GVHD were 36 and 31 percent, respectively. No grade 4 toxicities were seen.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         15 of 16 patients engrafted, of whom 11 achieved full or high-level mixed chimerism in both lymphoid and myeloid lineages.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         At a median follow-up of 40 months post-HCT, 13 of the 16 patients (81 percent) were alive and cured of their underlying disease.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H10">
         <span class="h2">
          Radiolabeled Mabs
         </span>
         <span class="headingEndMark">
          —
         </span>
         Monoclonal antibodies (Mab) conjugated with high energy emitting radioisotopes have been used to increase the radiation dose to tumor cells in bone marrow and reduce doses to other organs, such as the liver, lungs, and kidneys. This approach has not been widely adopted for conditioning regimens.
        </p>
        <p>
         There remains concern that high doses of radioactivity in the marrow space may injure or kill stromal cells. In addition, the delivery of such high doses of some radioisotopes requires sophisticated expertise, equipment, and shielding of the patient to avoid risk to health care workers.
        </p>
        <p class="headingAnchor" id="H9952231">
         <span class="h3">
          Anti-CD20 radioimmunoconjugates
         </span>
         <span class="headingEndMark">
          —
         </span>
         Anti-CD20 radioimmunoconjugates have been used to treat patients with B cell non-Hodgkin lymphoma (NHL). As an example,
         <a class="drug drug_general" data-topicid="8709" href="/z/d/drug information/8709.html" rel="external">
          ibritumomab tiuxetan
         </a>
         is a murine anti-CD20 monoclonal antibody conjugated to yttrium-90.
        </p>
        <p>
         Addition of anti-CD20 radioimmunoconjugates to standard preparative regimens for autologous transplantation in patients with B cell NHL provided encouraging preliminary results and tolerable toxicity profiles [
         <a href="#rid97">
          97-100
         </a>
         ]. A randomized trial reported similar progression-free survival and OS for BEAM plus anti-CD20 radioimmunoconjugates versus BEAM alone [
         <a href="#rid101">
          101
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H11">
         <span class="h3">
          Anti-CD45 antibody
         </span>
         <span class="headingEndMark">
          —
         </span>
         A monoclonal antibody directed against CD45, which is highly expressed on hematopoietic cells, allows targeting of radioisotopes to the marrow space [
         <a href="#rid102">
          102,103
         </a>
         ]. In one report, compared with registry data using Bu/Cy alone, addition of this monoclonal antibody to Bu/Cy was associated with a more favorable outcome [
         <a href="#rid104">
          104
         </a>
         ]. The difficulty of administering I-131 has limited use.
        </p>
        <p class="headingAnchor" id="H944694131">
         <span class="h3">
          Anti-CD66 antibody
         </span>
         <span class="headingEndMark">
          —
         </span>
         CD66 is highly expressed on normal myeloid cells from the promyelocyte to the mature granulocyte. In one report, 30 pediatric and adolescent patients undergoing allogeneic HCT for malignant (16 patients) or nonmalignant (14 patients) disorders underwent conditioning with yttrium-90 conjugated CD66 monoclonal antibody in combination with an RIC or MAC regimen [
         <a href="#rid105">
          105
         </a>
         ]. The combination of antibody plus RIC resulted in consistent myeloablation and stable complete donor chimerism in the setting of nonmalignant hematologic disease.
        </p>
        <p class="headingAnchor" id="H1143277">
         <span class="h2">
          Chimerism
         </span>
         <span class="headingEndMark">
          —
         </span>
         Chimerism refers to the coexistence of donor and host cells in the bone marrow. Chimerism is more common following nonmyeloablative or reduced intensity conditioning and following umbilical cord blood transplantation. For many genetic disorders, a state of mixed donor-host chimerism is sufficient to relieve the patient of disease-related manifestations (eg, beta thalassemia major). (See
         <a class="medical medical_review" href="/z/d/html/3555.html" rel="external">
          "Thalassemia: Management after hematopoietic cell transplantation"
         </a>
         .)
        </p>
        <p>
         In the light of reduced intensity of conditioning regimens, and with the induction of partial donor chimerism, donor leukocyte infusions [
         <a href="#rid106">
          106
         </a>
         ] or other immunotherapeutic interventions could be applied in an effort to balance the interactions between the following competing issues (see
         <a class="medical medical_review" href="/z/d/html/3552.html" rel="external">
          "Immunotherapy for the prevention and treatment of relapse following allogeneic hematopoietic cell transplantation"
         </a>
         ) [
         <a href="#rid79">
          79,107-115
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Maximizing the graft-versus-tumor effect
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Minimizing acute and chronic GVHD
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Minimizing graft rejection
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Minimizing opportunistic infections (eg, CMV infection) through rapid immune reconstitution [
         <a href="#rid116">
          116
         </a>
         ]
        </p>
        <p>
        </p>
        <p>
         This approach relies heavily on the serial assessment of chimerism, using techniques such as fluorescence in situ hybridization (FISH) or analysis of a variable number of tandem repeats (VNTR) between donor and recipient [
         <a href="#rid117">
          117-121
         </a>
         ]. In the setting of a sex-mismatched transplant, FISH for the X and Y chromosomes in interphase nuclei is a highly accurate technique for identifying chimerism.
        </p>
        <p class="headingAnchor" id="H16">
         <span class="h1">
          INFORMATION FOR PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5
         <sup>
          th
         </sup>
         to 6
         <sup>
          th
         </sup>
         grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10
         <sup>
          th
         </sup>
         to 12
         <sup>
          th
         </sup>
         grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
        </p>
        <p>
         Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient education" and the keyword(s) of interest.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Beyond the Basics topics (see
         <a class="medical medical_patient" href="/z/d/html/686.html" rel="external">
          "Patient education: Hematopoietic cell transplantation (bone marrow transplantation) (Beyond the Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H103575063">
         <span class="h1">
          SUMMARY
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Description
         </strong>
         – The preparative (conditioning) regimen is a critical element in the hematopoietic cell transplant (HCT) procedure. The purpose of the preparative regimen is twofold:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         To provide adequate immunosuppression to prevent rejection of the transplanted graft
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         To treat the disease for which the transplant is being performed
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Categories
         </strong>
         – Preparative regimens for HCT differ regarding agents (eg, chemotherapy, immunotherapy, radiation therapy), intensity, and degree of myeloablation. Generally accepted definitions follow (
         <a class="graphic graphic_table graphicRef90901" href="/z/d/graphic/90901.html" rel="external">
          table 1
         </a>
         ):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Myeloablative conditioning
         </strong>
         – A myeloablative conditioning (MAC) regimen consists of a single agent or combination of agents expected to destroy the hematopoietic cells in the bone marrow and produce profound pancytopenia. The resulting pancytopenia is long-lasting and usually irreversible unless hematopoiesis is restored by infusion of hematopoietic stem cells. Examples include total body irradiation ≥5 Gy or
         <a class="drug drug_general" data-topicid="9173" href="/z/d/drug information/9173.html" rel="external">
          busulfan
         </a>
         &gt;8 mg/kg orally. (See
         <a class="local">
          'Myeloablative regimens'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Nonmyeloablative conditioning
         </strong>
         – A nonmyeloablative (NMA) conditioning regimen is one that will cause minimal cytopenia (but significant lymphopenia) by itself and does not require stem cell support. Examples include
         <a class="drug drug_general" data-topicid="8452" href="/z/d/drug information/8452.html" rel="external">
          fludarabine
         </a>
         plus
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         with or without antithymocyte globulin or total body irradiation ≤2 Gy with or without a purine analog. However, the transplant, when given in this setting usually results in full donor engraftment because the engrafting donor T cells will eventually eliminate host hematopoietic cells, allowing the establishment of donor hematopoiesis. (See
         <a class="local">
          'NMA and RIC regimens'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Reduced intensity conditioning
         </strong>
         – Reduced intensity conditioning (RIC) regimens are an intermediate category of regimens that do not fit the definition of MAC or NMA. Such regimens cause cytopenias, which may be prolonged and result in significant morbidity and mortality and require stem cell support. Regimens generally considered as reduced intensity include ≤8 mg/kg of oral
         <a class="drug drug_general" data-topicid="9173" href="/z/d/drug information/9173.html" rel="external">
          busulfan
         </a>
         , or ≤140 mg/m
         <sup>
          2
         </sup>
         of
         <a class="drug drug_general" data-topicid="9605" href="/z/d/drug information/9605.html" rel="external">
          melphalan
         </a>
         .
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Choice of MAC regimen
         </strong>
         – Selection of a regimen is generally informed by institutional and physician preference and experience. Few randomized trials directly compare the efficacy of one MAC preparative regimen with another for particular diseases. (See
         <a class="local">
          'Choice of regimen'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          MAC versus RIC/NMA regimens
         </strong>
         – MAC regimens are generally associated with lower rates of relapse but higher rates of treatment mortality and morbidity; as a result, most studies suggest comparable overall survival with MAC versus RIC/NMA regimens. (See
         <a class="local">
          'MAC versus RIC regimens'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Adverse effects
         </strong>
         – All preparative regimens have short-term and long-term adverse effects, in addition to myelotoxicity. Other common toxicities include mucositis, nausea and vomiting, alopecia, diarrhea, rash, peripheral neuropathy, infertility, interstitial lung disease, and sinusoidal obstructive syndrome. Long-term complications following total body irradiation also include asymptomatic alterations in pulmonary function, cataracts, sicca syndrome, and thyroid dysfunction. (See
         <a class="local">
          'MAC toxicity'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p>
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Khouri IF, Keating M, Körbling M, et al. Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies. J Clin Oncol 1998; 16:2817.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Champlin R, Khouri I, Shimoni A, et al. Harnessing graft-versus-malignancy: non-myeloablative preparative regimens for allogeneic haematopoietic transplantation, an evolving strategy for adoptive immunotherapy. Br J Haematol 2000; 111:18.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Giralt S, Ballen K, Rizzo D, et al. Reduced-intensity conditioning regimen workshop: defining the dose spectrum. Report of a workshop convened by the center for international blood and marrow transplant research. Biol Blood Marrow Transplant 2009; 15:367.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bacigalupo A, Ballen K, Rizzo D, et al. Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transplant 2009; 15:1628.
          </a>
         </li>
         <li class="breakAll">
          Gratwohl A, Carreras E. Principles of Conditioning. In: ESH-EBMT Handbook on Haematopoietic Stem Cell Transplantation 2012, 6th edition, Apperley J, Carreras E, Gluckman E, Masszi T (Eds), European School of Haematology, Paris 2012. p.126.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ringdén O, Remberger M, Ruutu T, et al. Increased risk of chronic graft-versus-host disease, obstructive bronchiolitis, and alopecia with busulfan versus total body irradiation: long-term results of a randomized trial in allogeneic marrow recipients with leukemia. Nordic Bone Marrow Transplantation Group. Blood 1999; 93:2196.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hassan M. The role of busulfan in bone marrow transplantation. Med Oncol 1999; 16:166.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Buckner CD, Epstein RB, Rudolph RH, et al. Allogeneic marrow engraftment following whole body irradiation in a patient with leukemia. Blood 1970; 35:741.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shank B, Chu FC, Dinsmore R, et al. Hyperfractionated total body irradiation for bone marrow transplantation. Results in seventy leukemia patients with allogeneic transplants. Int J Radiat Oncol Biol Phys 1983; 9:1607.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Clift RA, Buckner CD, Appelbaum FR, et al. Allogeneic marrow transplantation in patients with acute myeloid leukemia in first remission: a randomized trial of two irradiation regimens. Blood 1990; 76:1867.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Clift RA, Buckner CD, Appelbaum FR, et al. Allogeneic marrow transplantation in patients with chronic myeloid leukemia in the chronic phase: a randomized trial of two irradiation regimens. Blood 1991; 77:1660.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thomas E, Storb R, Clift RA, et al. Bone-marrow transplantation (first of two parts). N Engl J Med 1975; 292:832.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thomas ED, Clift RA, Hersman J, et al. Marrow transplantation for acute nonlymphoblastic leukemic in first remission using fractionated or single-dose irradiation. Int J Radiat Oncol Biol Phys 1982; 8:817.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Santos GW, Sensenbrenner LL, Burke PJ, et al. Allogeneic marrow grafts in man using cyclophosphamide. Transplant Proc 1974; 6:345.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Blume KG, Forman SJ, O'Donnell MR, et al. Total body irradiation and high-dose etoposide: a new preparatory regimen for bone marrow transplantation in patients with advanced hematologic malignancies. Blood 1987; 69:1015.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Snyder DS, Chao NJ, Amylon MD, et al. Fractionated total body irradiation and high-dose etoposide as a preparatory regimen for bone marrow transplantation for 99 patients with acute leukemia in first complete remission. Blood 1993; 82:2920.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Snyder DS, Negrin RS, O'Donnell MR, et al. Fractionated total-body irradiation and high-dose etoposide as a preparatory regimen for bone marrow transplantation for 94 patients with chronic myelogenous leukemia in chronic phase. Blood 1994; 84:1672.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Long GD, Amylon MD, Stockerl-Goldstein KE, et al. Fractionated total-body irradiation, etoposide, and cyclophosphamide followed by allogeneic bone marrow transplantation for patients with high-risk or advanced-stage hematological malignancies. Biol Blood Marrow Transplant 1997; 3:324.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Horning SJ, Negrin RS, Chao JC, et al. Fractionated total-body irradiation, etoposide, and cyclophosphamide plus autografting in Hodgkin's disease and non-Hodgkin's lymphoma. J Clin Oncol 1994; 12:2552.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Weaver CH, Petersen FB, Appelbaum FR, et al. High-dose fractionated total-body irradiation, etoposide, and cyclophosphamide followed by autologous stem-cell support in patients with malignant lymphoma. J Clin Oncol 1994; 12:2559.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Riddell S, Appelbaum FR, Buckner CD, et al. High-dose cytarabine and total body irradiation with or without cyclophosphamide as a preparative regimen for marrow transplantation for acute leukemia. J Clin Oncol 1988; 6:576.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jillella AP, Doria R, Khan K, et al. Cyclophosphamide, cytosine arabinoside and TBI as a conditioning regimen for allogeneic bone marrow transplantation in patients with leukemia. Bone Marrow Transplant 1999; 23:1095.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Woods WG, Ramsay NK, Weisdorf DJ, et al. Bone marrow transplantation for acute lymphocytic leukemia utilizing total body irradiation followed by high doses of cytosine arabinoside: lack of superiority over cyclophosphamide-containing conditioning regimens. Bone Marrow Transplant 1990; 6:9.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thomas O, Mahé M, Campion L, et al. Long-term complications of total body irradiation in adults. Int J Radiat Oncol Biol Phys 2001; 49:125.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gopal R, Ha CS, Tucker SL, et al. Comparison of two total body irradiation fractionation regimens with respect to acute and late pulmonary toxicity. Cancer 2001; 92:1949.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Copelan EA, Deeg HJ. Conditioning for allogeneic marrow transplantation in patients with lymphohematopoietic malignancies without the use of total body irradiation. Blood 1992; 80:1648.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shah AB, Hartsell WF, Ghalie R, Kaizer H. Patterns of failure following bone marrow transplantation for metastatic breast cancer: the role of consolidative local therapy. Int J Radiat Oncol Biol Phys 1995; 32:1433.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tutschka PJ, Copelan EA, Klein JP. Bone marrow transplantation for leukemia following a new busulfan and cyclophosphamide regimen. Blood 1987; 70:1382.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Clift RA, Buckner CD, Thomas ED, et al. Marrow transplantation for chronic myeloid leukemia: a randomized study comparing cyclophosphamide and total body irradiation with busulfan and cyclophosphamide. Blood 1994; 84:2036.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           O'Donnell MR, Long GD, Parker PM, et al. Busulfan/cyclophosphamide as conditioning regimen for allogeneic bone marrow transplantation for myelodysplasia. J Clin Oncol 1995; 13:2973.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Santos GW, Tutschka PJ, Brookmeyer R, et al. Marrow transplantation for acute nonlymphocytic leukemia after treatment with busulfan and cyclophosphamide. N Engl J Med 1983; 309:1347.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Copelan EA, Biggs JC, Avalos BR, et al. Radiation-free preparation for allogeneic bone marrow transplantation in adults with acute lymphoblastic leukemia. J Clin Oncol 1992; 10:237.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lucarelli G, Galimberti M, Giardini C, et al. Bone marrow transplantation in thalassemia. The experience of Pesaro. Ann N Y Acad Sci 1998; 850:270.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lee JH, Joo YD, Kim H, et al. Randomized trial of myeloablative conditioning regimens: busulfan plus cyclophosphamide versus busulfan plus fludarabine. J Clin Oncol 2013; 31:701.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gaspard MH, Maraninchi D, Stoppa AM, et al. Intensive chemotherapy with high doses of BCNU, etoposide, cytosine arabinoside, and melphalan (BEAM) followed by autologous bone marrow transplantation: toxicity and antitumor activity in 26 patients with poor-risk malignancies. Cancer Chemother Pharmacol 1988; 22:256.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chao NJ, Stein AS, Long GD, et al. Busulfan/etoposide--initial experience with a new preparatory regimen for autologous bone marrow transplantation in patients with acute nonlymphoblastic leukemia. Blood 1993; 81:319.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Linker CA, Ries CA, Damon LE, et al. Autologous bone marrow transplantation for acute myeloid leukemia using busulfan plus etoposide as a preparative regimen. Blood 1993; 81:311.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wheeler C, Antin JH, Churchill WH, et al. Cyclophosphamide, carmustine, and etoposide with autologous bone marrow transplantation in refractory Hodgkin's disease and non-Hodgkin's lymphoma: a dose-finding study. J Clin Oncol 1990; 8:648.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Reece DE, Barnett MJ, Connors JM, et al. Intensive chemotherapy with cyclophosphamide, carmustine, and etoposide followed by autologous bone marrow transplantation for relapsed Hodgkin's disease. J Clin Oncol 1991; 9:1871.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Reece DE, Connors JM, Spinelli JJ, et al. Intensive therapy with cyclophosphamide, carmustine, etoposide +/- cisplatin, and autologous bone marrow transplantation for Hodgkin's disease in first relapse after combination chemotherapy. Blood 1994; 83:1193.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Slattery JT, Clift RA, Buckner CD, et al. Marrow transplantation for chronic myeloid leukemia: the influence of plasma busulfan levels on the outcome of transplantation. Blood 1997; 89:3055.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schuler US, Renner UD, Kroschinsky F, et al. Intravenous busulphan for conditioning before autologous or allogeneic human blood stem cell transplantation. Br J Haematol 2001; 114:944.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Radich JP, Gooley T, Bensinger W, et al. HLA-matched related hematopoietic cell transplantation for chronic-phase CML using a targeted busulfan and cyclophosphamide preparative regimen. Blood 2003; 102:31.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Peters WP, Shpall EJ, Jones RB, et al. High-dose combination alkylating agents with bone marrow support as initial treatment for metastatic breast cancer. J Clin Oncol 1988; 6:1368.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Valteau D, Hartmann O, Benhamou E, et al. Nonbacterial nonfungal interstitial pneumonitis following autologous bone marrow transplantation in children treated with high-dose chemotherapy without total-body irradiation. Transplantation 1988; 45:737.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schiffman K, Buckner CD, Maziarz R, et al. High-dose busulfan, melphalan, and thiotepa followed by autologous peripheral blood stem cell transplantation in patients with aggressive lymphoma or relapsed Hodgkin's disease. Biol Blood Marrow Transplant 1997; 3:261.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Storb R, Leisenring W, Anasetti C, et al. Long-term follow-up of allogeneic marrow transplants in patients with aplastic anemia conditioned by cyclophosphamide combined with antithymocyte globulin. Blood 1997; 89:3890.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Liu HW, Seftel MD, Rubinger M, et al. Total body irradiation compared with BEAM: Long-term outcomes of peripheral blood autologous stem cell transplantation for non-Hodgkin's lymphoma. Int J Radiat Oncol Biol Phys 2010; 78:513.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hartman AR, Williams SF, Dillon JJ. Survival, disease-free survival and adverse effects of conditioning for allogeneic bone marrow transplantation with busulfan/cyclophosphamide vs total body irradiation: a meta-analysis. Bone Marrow Transplant 1998; 22:439.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Litzow MR, Pérez WS, Klein JP, et al. Comparison of outcome following allogeneic bone marrow transplantation with cyclophosphamide-total body irradiation versus busulphan-cyclophosphamide conditioning regimens for acute myelogenous leukaemia in first remission. Br J Haematol 2002; 119:1115.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Childs R, Srinivasan R. Advances in allogeneic stem cell transplantation: directing graft-versus-leukemia at solid tumors. Cancer J 2002; 8:2.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Champlin R, Khouri I, Kornblau S, et al. Reinventing bone marrow transplantation: reducing toxicity using nonmyeloablative, preparative regimens and induction of graft-versus-malignancy. Curr Opin Oncol 1999; 11:87.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Craddock C. Nonmyeloablative stem cell transplants. Curr Opin Hematol 1999; 6:383.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Little MT, Storb R. The future of allogeneic hematopoietic stem cell transplantation: minimizing pain, maximizing gain. J Clin Invest 2000; 105:1679.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Barrett J, Childs R. Non-myeloablative stem cell transplants. Br J Haematol 2000; 111:6.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Carvallo C, Geller N, Kurlander R, et al. Prior chemotherapy and allograft CD34+ dose impact donor engraftment following nonmyeloablative allogeneic stem cell transplantation in patients with solid tumors. Blood 2004; 103:1560.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Childs R, Chernoff A, Contentin N, et al. Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. N Engl J Med 2000; 343:750.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Uzunel M, Mattsson J, Brune M, et al. Kinetics of minimal residual disease and chimerism in patients with chronic myeloid leukemia after nonmyeloablative conditioning and allogeneic stem cell transplantation. Blood 2003; 101:469.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Storb R, Gyurkocza B, Storer BE, et al. Graft-versus-host disease and graft-versus-tumor effects after allogeneic hematopoietic cell transplantation. J Clin Oncol 2013; 31:1530.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Saito T, Kanda Y, Kami M, et al. Therapeutic potential of a reduced-intensity preparative regimen for allogeneic transplantation with cladribine, busulfan, and antithymocyte globulin against advanced/refractory acute leukemia/lymphoma. Clin Cancer Res 2002; 8:1014.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Niederwieser D, Maris M, Shizuru JA, et al. Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induce durable complete chimerism and sustained remissions in patients with hematological diseases. Blood 2003; 101:1620.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Belkacémi Y, Labopin M, Hennequin C, et al. Reduced-intensity conditioning regimen using low-dose total body irradiation before allogeneic transplant for hematologic malignancies: Experience from the European Group for Blood and Marrow Transplantation. Int J Radiat Oncol Biol Phys 2007; 67:544.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Diaconescu R, Flowers CR, Storer B, et al. Morbidity and mortality with nonmyeloablative compared with myeloablative conditioning before hematopoietic cell transplantation from HLA-matched related donors. Blood 2004; 104:1550.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Alyea EP, Kim HT, Ho V, et al. Comparative outcome of nonmyeloablative and myeloablative allogeneic hematopoietic cell transplantation for patients older than 50 years of age. Blood 2005; 105:1810.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Corradini P, Zallio F, Mariotti J, et al. Effect of age and previous autologous transplantation on nonrelapse mortality and survival in patients treated with reduced-intensity conditioning and allografting for advanced hematologic malignancies. J Clin Oncol 2005; 23:6690.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Baron F, Storb R, Storer BE, et al. Factors associated with outcomes in allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning after failed myeloablative hematopoietic cell transplantation. J Clin Oncol 2006; 24:4150.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pulsipher MA, Boucher KM, Wall D, et al. Reduced-intensity allogeneic transplantation in pediatric patients ineligible for myeloablative therapy: results of the Pediatric Blood and Marrow Transplant Consortium Study ONC0313. Blood 2009; 114:1429.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McClune BL, Weisdorf DJ. Reduced-intensity conditioning allogeneic stem cell transplantation for older adults: is it the standard of care? Curr Opin Hematol 2010; 17:133.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hermann S, Klein SA, Jacobi V, et al. Older patients with high-risk fungal infections can be successfully allografted using non-myeloablative conditioning in combination with intensified supportive care regimens. Br J Haematol 2001; 113:446.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Blaise D, Bay JO, Faucher C, et al. Reduced-intensity preparative regimen and allogeneic stem cell transplantation for advanced solid tumors. Blood 2004; 103:435.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           MacKinnon S. Who may benefit from donor leucocyte infusions after allogeneic stem cell transplantation? Br J Haematol 2000; 110:12.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kahl C, Storer BE, Sandmaier BM, et al. Relapse risk in patients with malignant diseases given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. Blood 2007; 110:2744.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sorror ML, Maris MB, Storb R, et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 2005; 106:2912.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Teshima T, Matsuo K, Matsue K, et al. Impact of human leucocyte antigen mismatch on graft-versus-host disease and graft failure after reduced intensity conditioning allogeneic haematopoietic stem cell transplantation from related donors. Br J Haematol 2005; 130:575.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rizzieri DA, Koh LP, Long GD, et al. Partially matched, nonmyeloablative allogeneic transplantation: clinical outcomes and immune reconstitution. J Clin Oncol 2007; 25:690.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Liesveld JL, Rothberg PG. Mixed chimerism in SCT: conflict or peaceful coexistence? Bone Marrow Transplant 2008; 42:297.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ciurea SO, Saliba R, Rondon G, et al. Reduced-intensity conditioning using fludarabine, melphalan and thiotepa for adult patients undergoing haploidentical SCT. Bone Marrow Transplant 2010; 45:429.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pillai AB, George TI, Dutt S, Strober S. Host natural killer T cells induce an interleukin-4-dependent expansion of donor CD4+CD25+Foxp3+ T regulatory cells that protects against graft-versus-host disease. Blood 2009; 113:4458.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lowsky R, Takahashi T, Liu YP, et al. Protective conditioning for acute graft-versus-host disease. N Engl J Med 2005; 353:1321.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kohrt HE, Turnbull BB, Heydari K, et al. TLI and ATG conditioning with low risk of graft-versus-host disease retains antitumor reactions after allogeneic hematopoietic cell transplantation from related and unrelated donors. Blood 2009; 114:1099.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Baron F, Zachée P, Maertens J, et al. Non-myeloablative allogeneic hematopoietic cell transplantation following fludarabine plus 2 Gy TBI or ATG plus 8 Gy TLI: a phase II randomized study from the Belgian Hematological Society. J Hematol Oncol 2015; 8:4.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Beelen DW, Trenschel R, Stelljes M, et al. Treosulfan or busulfan plus fludarabine as conditioning treatment before allogeneic haemopoietic stem cell transplantation for older patients with acute myeloid leukaemia or myelodysplastic syndrome (MC-FludT.14/L): a randomised, non-inferiority, phase 3 trial. Lancet Haematol 2020; 7:e28.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Scott BL, Pasquini MC, Logan BR, et al. Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes. J Clin Oncol 2017; 35:1154.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hourigan CS, Dillon LW, Gui G, et al. Impact of Conditioning Intensity of Allogeneic Transplantation for Acute Myeloid Leukemia With Genomic Evidence of Residual Disease. J Clin Oncol 2020; 38:1273.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lioure B, Béné MC, Pigneux A, et al. Early matched sibling hematopoietic cell transplantation for adult AML in first remission using an age-adapted strategy: long-term results of a prospective GOELAMS study. Blood 2012; 119:2943.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aoudjhane M, Labopin M, Gorin NC, et al. Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic haematopoietic stem cell transplantation for patients older than 50 years of age with acute myeloblastic leukaemia: a retrospective survey from the Acute Leukemia Working Party (ALWP) of the European group for Blood and Marrow Transplantation (EBMT). Leukemia 2005; 19:2304.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Scott BL, Sandmaier BM, Storer B, et al. Myeloablative vs nonmyeloablative allogeneic transplantation for patients with myelodysplastic syndrome or acute myelogenous leukemia with multilineage dysplasia: a retrospective analysis. Leukemia 2006; 20:128.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shimoni A, Hardan I, Shem-Tov N, et al. Allogeneic hematopoietic stem-cell transplantation in AML and MDS using myeloablative versus reduced-intensity conditioning: the role of dose intensity. Leukemia 2006; 20:322.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Martino R, Iacobelli S, Brand R, et al. Retrospective comparison of reduced-intensity conditioning and conventional high-dose conditioning for allogeneic hematopoietic stem cell transplantation using HLA-identical sibling donors in myelodysplastic syndromes. Blood 2006; 108:836.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Alyea EP, Kim HT, Ho V, et al. Impact of conditioning regimen intensity on outcome of allogeneic hematopoietic cell transplantation for advanced acute myelogenous leukemia and myelodysplastic syndrome. Biol Blood Marrow Transplant 2006; 12:1047.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Flynn CM, Hirsch B, Defor T, et al. Reduced intensity compared with high dose conditioning for allotransplantation in acute myeloid leukemia and myelodysplastic syndrome: a comparative clinical analysis. Am J Hematol 2007; 82:867.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ringdén O, Labopin M, Ehninger G, et al. Reduced intensity conditioning compared with myeloablative conditioning using unrelated donor transplants in patients with acute myeloid leukemia. J Clin Oncol 2009; 27:4570.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Luger SM, Ringdén O, Zhang MJ, et al. Similar outcomes using myeloablative vs reduced-intensity allogeneic transplant preparative regimens for AML or MDS. Bone Marrow Transplant 2012; 47:203.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gyurkocza B, Storb R, Storer BE, et al. Nonmyeloablative allogeneic hematopoietic cell transplantation in patients with acute myeloid leukemia. J Clin Oncol 2010; 28:2859.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Eapen M, Brazauskas R, Hemmer M, et al. Hematopoietic cell transplant for acute myeloid leukemia and myelodysplastic syndrome: conditioning regimen intensity. Blood Adv 2018; 2:2095.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Straathof KC, Rao K, Eyrich M, et al. Haemopoietic stem-cell transplantation with antibody-based minimal-intensity conditioning: a phase 1/2 study. Lancet 2009; 374:912.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gopal AK, Rajendran JG, Gooley TA, et al. High-dose [131I]tositumomab (anti-CD20) radioimmunotherapy and autologous hematopoietic stem-cell transplantation for adults &gt; or = 60 years old with relapsed or refractory B-cell lymphoma. J Clin Oncol 2007; 25:1396.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Krishnan A, Nademanee A, Fung HC, et al. Phase II trial of a transplantation regimen of yttrium-90 ibritumomab tiuxetan and high-dose chemotherapy in patients with non-Hodgkin's lymphoma. J Clin Oncol 2008; 26:90.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gopal AK, Guthrie KA, Rajendran J, et al. ⁹⁰Y-Ibritumomab tiuxetan, fludarabine, and TBI-based nonmyeloablative allogeneic transplantation conditioning for patients with persistent high-risk B-cell lymphoma. Blood 2011; 118:1132.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Devizzi L, Guidetti A, Seregni E, et al. Long-Term Results of Autologous Hematopoietic Stem-Cell Transplantation After High-Dose 90Y-Ibritumomab Tiuxetan for Patients With Poor-Risk Non-Hodgkin Lymphoma Not Eligible for High-Dose BEAM. J Clin Oncol 2013; 31:2974.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vose JM, Carter S, Burns LJ, et al. Phase III randomized study of rituximab/carmustine, etoposide, cytarabine, and melphalan (BEAM) compared with iodine-131 tositumomab/BEAM with autologous hematopoietic cell transplantation for relapsed diffuse large B-cell lymphoma: results from the BMT CTN 0401 trial. J Clin Oncol 2013; 31:1662.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Matthews DC, Appelbaum FR, Eary JF, et al. Development of a marrow transplant regimen for acute leukemia using targeted hematopoietic irradiation delivered by 131I-labeled anti-CD45 antibody, combined with cyclophosphamide and total body irradiation. Blood 1995; 85:1122.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Matthews DC, Appelbaum FR, Eary JF, et al. Phase I study of (131)I-anti-CD45 antibody plus cyclophosphamide and total body irradiation for advanced acute leukemia and myelodysplastic syndrome. Blood 1999; 94:1237.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pagel JM, Appelbaum FR, Eary JF, et al. 131I-anti-CD45 antibody plus busulfan and cyclophosphamide before allogeneic hematopoietic cell transplantation for treatment of acute myeloid leukemia in first remission. Blood 2006; 107:2184.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schulz AS, Glatting G, Hoenig M, et al. Radioimmunotherapy-based conditioning for hematopoietic cell transplantation in children with malignant and nonmalignant diseases. Blood 2011; 117:4642.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bethge WA, Hegenbart U, Stuart MJ, et al. Adoptive immunotherapy with donor lymphocyte infusions after allogeneic hematopoietic cell transplantation following nonmyeloablative conditioning. Blood 2004; 103:790.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sorror ML, Maris MB, Storer B, et al. Comparing morbidity and mortality of HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative and myeloablative conditioning: influence of pretransplantation comorbidities. Blood 2004; 104:961.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Corradini P, Tarella C, Olivieri A, et al. Reduced-intensity conditioning followed by allografting of hematopoietic cells can produce clinical and molecular remissions in patients with poor-risk hematologic malignancies. Blood 2002; 99:75.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chakraverty R, Peggs K, Chopra R, et al. Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimen. Blood 2002; 99:1071.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Marks DI, Lush R, Cavenagh J, et al. The toxicity and efficacy of donor lymphocyte infusions given after reduced-intensity conditioning allogeneic stem cell transplantation. Blood 2002; 100:3108.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mielcarek M, Martin PJ, Leisenring W, et al. Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation. Blood 2003; 102:756.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mohty M, Bay JO, Faucher C, et al. Graft-versus-host disease following allogeneic transplantation from HLA-identical sibling with antithymocyte globulin-based reduced-intensity preparative regimen. Blood 2003; 102:470.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Peggs KS, Thomson K, Hart DP, et al. Dose-escalated donor lymphocyte infusions following reduced intensity transplantation: toxicity, chimerism, and disease responses. Blood 2004; 103:1548.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Narimatsu H, Kami M, Miyakoshi S, et al. Graft failure following reduced-intensity cord blood transplantation for adult patients. Br J Haematol 2006; 132:36.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sala-Torra O, Martin PJ, Storer B, et al. Serious acute or chronic graft-versus-host disease after hematopoietic cell transplantation: a comparison of myeloablative and nonmyeloablative conditioning regimens. Bone Marrow Transplant 2008; 41:887.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chen X, Hale GA, Barfield R, et al. Rapid immune reconstitution after a reduced-intensity conditioning regimen and a CD3-depleted haploidentical stem cell graft for paediatric refractory haematological malignancies. Br J Haematol 2006; 135:524.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wäsch R, Bertz H, Kunzmann R, Finke J. Incidence of mixed chimaerism and clinical outcome in 101 patients after myeloablative conditioning regimens and allogeneic stem cell transplantation. Br J Haematol 2000; 109:743.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           de Weger RA, Tilanus MG, Scheidel KC, et al. Monitoring of residual disease and guided donor leucocyte infusion after allogeneic bone marrow transplantation by chimaerism analysis with short tandem repeats. Br J Haematol 2000; 110:647.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Baron F, Baker JE, Storb R, et al. Kinetics of engraftment in patients with hematologic malignancies given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. Blood 2004; 104:2254.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bader P, Niethammer D, Willasch A, et al. How and when should we monitor chimerism after allogeneic stem cell transplantation? Bone Marrow Transplant 2005; 35:107.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Michallet AS, Fürst S, Le QH, et al. Impact of chimaerism analysis and kinetics on allogeneic haematopoietic stem cell transplantation outcome after conventional and reduced-intensity conditioning regimens. Br J Haematol 2005; 128:676.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 3557 Version 34.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9704734" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11091179" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Harnessing graft-versus-malignancy: non-myeloablative preparative regimens for allogeneic haematopoietic transplantation, an evolving strategy for adoptive immunotherapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19203728" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Reduced-intensity conditioning regimen workshop: defining the dose spectrum. Report of a workshop convened by the center for international blood and marrow transplant research.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19896087" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Defining the intensity of conditioning regimens: working definitions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19896087" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Defining the intensity of conditioning regimens: working definitions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10090927" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Increased risk of chronic graft-versus-host disease, obstructive bronchiolitis, and alopecia with busulfan versus total body irradiation: long-term results of a randomized trial in allogeneic marrow recipients with leukemia. Nordic Bone Marrow Transplantation Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10523796" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : The role of busulfan in bone marrow transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4913404" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Allogeneic marrow engraftment following whole body irradiation in a patient with leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6358154" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Hyperfractionated total body irradiation for bone marrow transplantation. Results in seventy leukemia patients with allogeneic transplants.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2224134" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Allogeneic marrow transplantation in patients with acute myeloid leukemia in first remission: a randomized trial of two irradiation regimens.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2015394" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Allogeneic marrow transplantation in patients with chronic myeloid leukemia in the chronic phase: a randomized trial of two irradiation regimens.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/234595" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Bone-marrow transplantation (first of two parts).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7050046" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Marrow transplantation for acute nonlymphoblastic leukemic in first remission using fractionated or single-dose irradiation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4155151" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Allogeneic marrow grafts in man using cyclophosphamide.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3548841" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Total body irradiation and high-dose etoposide: a new preparatory regimen for bone marrow transplantation in patients with advanced hematologic malignancies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8219241" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Fractionated total body irradiation and high-dose etoposide as a preparatory regimen for bone marrow transplantation for 99 patients with acute leukemia in first complete remission.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8068956" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Fractionated total-body irradiation and high-dose etoposide as a preparatory regimen for bone marrow transplantation for 94 patients with chronic myelogenous leukemia in chronic phase.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9502300" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Fractionated total-body irradiation, etoposide, and cyclophosphamide followed by allogeneic bone marrow transplantation for patients with high-risk or advanced-stage hematological malignancies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7989928" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Fractionated total-body irradiation, etoposide, and cyclophosphamide plus autografting in Hodgkin's disease and non-Hodgkin's lymphoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7989929" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : High-dose fractionated total-body irradiation, etoposide, and cyclophosphamide followed by autologous stem-cell support in patients with malignant lymphoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3282031" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : High-dose cytarabine and total body irradiation with or without cyclophosphamide as a preparative regimen for marrow transplantation for acute leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10382947" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Cyclophosphamide, cytosine arabinoside and TBI as a conditioning regimen for allogeneic bone marrow transplantation in patients with leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2202462" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Bone marrow transplantation for acute lymphocytic leukemia utilizing total body irradiation followed by high doses of cytosine arabinoside: lack of superiority over cyclophosphamide-containing conditioning regimens.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11163505" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Long-term complications of total body irradiation in adults.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11745270" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Comparison of two total body irradiation fractionation regimens with respect to acute and late pulmonary toxicity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1391935" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Conditioning for allogeneic marrow transplantation in patients with lymphohematopoietic malignancies without the use of total body irradiation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7635784" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Patterns of failure following bone marrow transplantation for metastatic breast cancer: the role of consolidative local therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3311203" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Bone marrow transplantation for leukemia following a new busulfan and cyclophosphamide regimen.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8081005" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Marrow transplantation for chronic myeloid leukemia: a randomized study comparing cyclophosphamide and total body irradiation with busulfan and cyclophosphamide.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8523063" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Busulfan/cyclophosphamide as conditioning regimen for allogeneic bone marrow transplantation for myelodysplasia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6355849" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Marrow transplantation for acute nonlymphocytic leukemia after treatment with busulfan and cyclophosphamide.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1732424" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Radiation-free preparation for allogeneic bone marrow transplantation in adults with acute lymphoblastic leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9668548" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Bone marrow transplantation in thalassemia. The experience of Pesaro.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23129746" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Randomized trial of myeloablative conditioning regimens: busulfan plus cyclophosphamide versus busulfan plus fludarabine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3044633" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Intensive chemotherapy with high doses of BCNU, etoposide, cytosine arabinoside, and melphalan (BEAM) followed by autologous bone marrow transplantation: toxicity and antitumor activity in 26 patients with poor-risk malignancies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8422458" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Busulfan/etoposide--initial experience with a new preparatory regimen for autologous bone marrow transplantation in patients with acute nonlymphoblastic leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8422457" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Autologous bone marrow transplantation for acute myeloid leukemia using busulfan plus etoposide as a preparative regimen.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2313334" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Cyclophosphamide, carmustine, and etoposide with autologous bone marrow transplantation in refractory Hodgkin's disease and non-Hodgkin's lymphoma: a dose-finding study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1919637" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Intensive chemotherapy with cyclophosphamide, carmustine, and etoposide followed by autologous bone marrow transplantation for relapsed Hodgkin's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8118023" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Intensive therapy with cyclophosphamide, carmustine, etoposide +/- cisplatin, and autologous bone marrow transplantation for Hodgkin's disease in first relapse after combination chemotherapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9108427" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Marrow transplantation for chronic myeloid leukemia: the influence of plasma busulfan levels on the outcome of transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11564090" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Intravenous busulphan for conditioning before autologous or allogeneic human blood stem cell transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12595317" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : HLA-matched related hematopoietic cell transplantation for chronic-phase CML using a targeted busulfan and cyclophosphamide preparative regimen.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3047332" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : High-dose combination alkylating agents with bone marrow support as initial treatment for metastatic breast cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2833829" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Nonbacterial nonfungal interstitial pneumonitis following autologous bone marrow transplantation in children treated with high-dose chemotherapy without total-body irradiation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9450921" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : High-dose busulfan, melphalan, and thiotepa followed by autologous peripheral blood stem cell transplantation in patients with aggressive lymphoma or relapsed Hodgkin's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9160700" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Long-term follow-up of allogeneic marrow transplants in patients with aplastic anemia conditioned by cyclophosphamide combined with antithymocyte globulin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20137862" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Total body irradiation compared with BEAM: Long-term outcomes of peripheral blood autologous stem cell transplantation for non-Hodgkin's lymphoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9733266" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Survival, disease-free survival and adverse effects of conditioning for allogeneic bone marrow transplantation with busulfan/cyclophosphamide vs total body irradiation: a meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12472596" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Comparison of outcome following allogeneic bone marrow transplantation with cyclophosphamide-total body irradiation versus busulphan-cyclophosphamide conditioning regimens for acute myelogenous leukaemia in first remission.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11895199" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Advances in allogeneic stem cell transplantation: directing graft-versus-leukemia at solid tumors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10188072" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Reinventing bone marrow transplantation: reducing toxicity using nonmyeloablative, preparative regimens and induction of graft-versus-malignancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10546791" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Nonmyeloablative stem cell transplants.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10862782" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : The future of allogeneic hematopoietic stem cell transplantation: minimizing pain, maximizing gain.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11091178" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Non-myeloablative stem cell transplants.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14551148" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Prior chemotherapy and allograft CD34+ dose impact donor engraftment following nonmyeloablative allogeneic stem cell transplantation in patients with solid tumors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10984562" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12393598" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Kinetics of minimal residual disease and chimerism in patients with chronic myeloid leukemia after nonmyeloablative conditioning and allogeneic stem cell transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23478054" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Graft-versus-host disease and graft-versus-tumor effects after allogeneic hematopoietic cell transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11948108" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Therapeutic potential of a reduced-intensity preparative regimen for allogeneic transplantation with cladribine, busulfan, and antithymocyte globulin against advanced/refractory acute leukemia/lymphoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12393457" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induce durable complete chimerism and sustained remissions in patients with hematological diseases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17141976" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Reduced-intensity conditioning regimen using low-dose total body irradiation before allogeneic transplant for hematologic malignancies: Experience from the European Group for Blood and Marrow Transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15150081" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Morbidity and mortality with nonmyeloablative compared with myeloablative conditioning before hematopoietic cell transplantation from HLA-matched related donors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15459007" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Comparative outcome of nonmyeloablative and myeloablative allogeneic hematopoietic cell transplantation for patients older than 50 years of age.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16170177" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Effect of age and previous autologous transplantation on nonrelapse mortality and survival in patients treated with reduced-intensity conditioning and allografting for advanced hematologic malignancies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16896000" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Factors associated with outcomes in allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning after failed myeloablative hematopoietic cell transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19528536" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Reduced-intensity allogeneic transplantation in pediatric patients ineligible for myeloablative therapy: results of the Pediatric Blood and Marrow Transplant Consortium Study ONC0313.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20071984" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Reduced-intensity conditioning allogeneic stem cell transplantation for older adults: is it the standard of care?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11380415" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Older patients with high-risk fungal infections can be successfully allografted using non-myeloablative conditioning in combination with intensified supportive care regimens.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12946991" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Reduced-intensity preparative regimen and allogeneic stem cell transplantation for advanced solid tumors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10930975" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Who may benefit from donor leucocyte infusions after allogeneic stem cell transplantation?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17595333" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Relapse risk in patients with malignant diseases given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15994282" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16098073" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Impact of human leucocyte antigen mismatch on graft-versus-host disease and graft failure after reduced intensity conditioning allogeneic haematopoietic stem cell transplantation from related donors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17228020" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Partially matched, nonmyeloablative allogeneic transplantation: clinical outcomes and immune reconstitution.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18660844" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Mixed chimerism in SCT: conflict or peaceful coexistence?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19668237" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Reduced-intensity conditioning using fludarabine, melphalan and thiotepa for adult patients undergoing haploidentical SCT.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19221040" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Host natural killer T cells induce an interleukin-4-dependent expansion of donor CD4+CD25+Foxp3+ T regulatory cells that protects against graft-versus-host disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16192477" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Protective conditioning for acute graft-versus-host disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19423725" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : TLI and ATG conditioning with low risk of graft-versus-host disease retains antitumor reactions after allogeneic hematopoietic cell transplantation from related and unrelated donors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25652604" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Non-myeloablative allogeneic hematopoietic cell transplantation following fludarabine plus 2 Gy TBI or ATG plus 8 Gy TLI: a phase II randomized study from the Belgian Hematological Society.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31606445" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Treosulfan or busulfan plus fludarabine as conditioning treatment before allogeneic haemopoietic stem cell transplantation for older patients with acute myeloid leukaemia or myelodysplastic syndrome (MC-FludT.14/L): a randomised, non-inferiority, phase 3 trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28380315" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31860405" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Impact of Conditioning Intensity of Allogeneic Transplantation for Acute Myeloid Leukemia With Genomic Evidence of Residual Disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22323482" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Early matched sibling hematopoietic cell transplantation for adult AML in first remission using an age-adapted strategy: long-term results of a prospective GOELAMS study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16193083" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic haematopoietic stem cell transplantation for patients older than 50 years of age with acute myeloblastic leukaemia: a retrospective survey from the Acute Leukemia Working Party (ALWP) of the European group for Blood and Marrow Transplantation (EBMT).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16270037" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : Myeloablative vs nonmyeloablative allogeneic transplantation for patients with myelodysplastic syndrome or acute myelogenous leukemia with multilineage dysplasia: a retrospective analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16307018" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : Allogeneic hematopoietic stem-cell transplantation in AML and MDS using myeloablative versus reduced-intensity conditioning: the role of dose intensity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16597592" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : Retrospective comparison of reduced-intensity conditioning and conventional high-dose conditioning for allogeneic hematopoietic stem cell transplantation using HLA-identical sibling donors in myelodysplastic syndromes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17067911" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : Impact of conditioning regimen intensity on outcome of allogeneic hematopoietic cell transplantation for advanced acute myelogenous leukemia and myelodysplastic syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17616969" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : Reduced intensity compared with high dose conditioning for allotransplantation in acute myeloid leukemia and myelodysplastic syndrome: a comparative clinical analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19652066" id="rid91" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          92 : Reduced intensity conditioning compared with myeloablative conditioning using unrelated donor transplants in patients with acute myeloid leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21441963" id="rid92" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          93 : Similar outcomes using myeloablative vs reduced-intensity allogeneic transplant preparative regimens for AML or MDS.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20439626" id="rid93" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          94 : Nonmyeloablative allogeneic hematopoietic cell transplantation in patients with acute myeloid leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30135184" id="rid94" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          95 : Hematopoietic cell transplant for acute myeloid leukemia and myelodysplastic syndrome: conditioning regimen intensity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19729196" id="rid95" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          96 : Haemopoietic stem-cell transplantation with antibody-based minimal-intensity conditioning: a phase 1/2 study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17312330" id="rid96" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          97 : High-dose [131I]tositumomab (anti-CD20) radioimmunotherapy and autologous hematopoietic stem-cell transplantation for adults&gt;or = 60 years old with relapsed or refractory B-cell lymphoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18025438" id="rid97" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          98 : Phase II trial of a transplantation regimen of yttrium-90 ibritumomab tiuxetan and high-dose chemotherapy in patients with non-Hodgkin's lymphoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21508413" id="rid98" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          99 : ⁹⁰Y-Ibritumomab tiuxetan, fludarabine, and TBI-based nonmyeloablative allogeneic transplantation conditioning for patients with persistent high-risk B-cell lymphoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23857974" id="rid99" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          100 : Long-Term Results of Autologous Hematopoietic Stem-Cell Transplantation After High-Dose 90Y-Ibritumomab Tiuxetan for Patients With Poor-Risk Non-Hodgkin Lymphoma Not Eligible for High-Dose BEAM.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23478060" id="rid100" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          101 : Phase III randomized study of rituximab/carmustine, etoposide, cytarabine, and melphalan (BEAM) compared with iodine-131 tositumomab/BEAM with autologous hematopoietic cell transplantation for relapsed diffuse large B-cell lymphoma: results from the BMT CTN 0401 trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7849300" id="rid101" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          102 : Development of a marrow transplant regimen for acute leukemia using targeted hematopoietic irradiation delivered by 131I-labeled anti-CD45 antibody, combined with cyclophosphamide and total body irradiation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10438711" id="rid102" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          103 : Phase I study of (131)I-anti-CD45 antibody plus cyclophosphamide and total body irradiation for advanced acute leukemia and myelodysplastic syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16254140" id="rid103" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          104 : 131I-anti-CD45 antibody plus busulfan and cyclophosphamide before allogeneic hematopoietic cell transplantation for treatment of acute myeloid leukemia in first remission.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21325170" id="rid104" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          105 : Radioimmunotherapy-based conditioning for hematopoietic cell transplantation in children with malignant and nonmalignant diseases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14525766" id="rid105" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          106 : Adoptive immunotherapy with donor lymphocyte infusions after allogeneic hematopoietic cell transplantation following nonmyeloablative conditioning.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15113759" id="rid106" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          107 : Comparing morbidity and mortality of HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative and myeloablative conditioning: influence of pretransplantation comorbidities.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11756155" id="rid107" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          108 : Reduced-intensity conditioning followed by allografting of hematopoietic cells can produce clinical and molecular remissions in patients with poor-risk hematologic malignancies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11807015" id="rid108" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          109 : Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimen.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12384406" id="rid109" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          110 : The toxicity and efficacy of donor lymphocyte infusions given after reduced-intensity conditioning allogeneic stem cell transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12663454" id="rid110" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          111 : Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12649133" id="rid111" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          112 : Graft-versus-host disease following allogeneic transplantation from HLA-identical sibling with antithymocyte globulin-based reduced-intensity preparative regimen.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14576063" id="rid112" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          113 : Dose-escalated donor lymphocyte infusions following reduced intensity transplantation: toxicity, chimerism, and disease responses.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16371018" id="rid113" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          114 : Graft failure following reduced-intensity cord blood transplantation for adult patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18209720" id="rid114" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          115 : Serious acute or chronic graft-versus-host disease after hematopoietic cell transplantation: a comparison of myeloablative and nonmyeloablative conditioning regimens.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17010105" id="rid115" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          116 : Rapid immune reconstitution after a reduced-intensity conditioning regimen and a CD3-depleted haploidentical stem cell graft for paediatric refractory haematological malignancies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10929024" id="rid116" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          117 : Incidence of mixed chimaerism and clinical outcome in 101 patients after myeloablative conditioning regimens and allogeneic stem cell transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10997977" id="rid117" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          118 : Monitoring of residual disease and guided donor leucocyte infusion after allogeneic bone marrow transplantation by chimaerism analysis with short tandem repeats.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15226174" id="rid118" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          119 : Kinetics of engraftment in patients with hematologic malignancies given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15502849" id="rid119" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          120 : How and when should we monitor chimerism after allogeneic stem cell transplantation?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15725090" id="rid120" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          121 : Impact of chimaerism analysis and kinetics on allogeneic haematopoietic stem cell transplantation outcome after conventional and reduced-intensity conditioning regimens.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
